Skip to main content

Table 2 Comparison of clinical characteristics in short-term responders and non-responders to tolvaptan

From: Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study

Variables

Responders

Non-responders

P (uni)

N

16 (53%)

14 (47%)

–

Age, years

71 [46–87]

65 [51–80]

0.227

Sex, M/F

8/8

9/5

0.484

ΔBW, at day 8, kg

−3.6 [−9.1 to −1.7]

−0.2 [−1.2 to + 2.5]

<.001***

Child-Pugh-Turcotte class, B/C

10/6

5/9

0.272

MELD score

13 [8–22]

16 [8–29]

0.164

MELDNa score

17 [8–30]

21 [12–32]

0.129

MAP, mmHg

81 [65–104]

82 [76–106]

0.533

Baseline diuretics

 Furosemide, mg/day

22.5 [0–60]

30 [0–160]

0.949

 Spironolactone, mg/day

50 [25–100]

37.5 [0–75]

0.443

Pre-treatment biochemical studies

 Total bilirubin, mg/dL

1.5 [0.3–12.6]

3.5 [1.1–8.3]

0.034*

 PT-INR

1.20 [0.96–1.75]

1.29 [1.03–2.42]

0.429

 Serum sodium, mmol/L

134.8 [123.1–142.8]

133.4 [122.3–40.0]

0.692

 Albumin, g/dL

2.5 [1.6–3.1]

2.4 [1.8–3.9]

0.917

 BUN, mg/dL

18.3 [5.9–47.1]

23.6 [11.9–46.3]

0.085

 Serum creatinine, mg/dL

1.00 [0.48–2.49]

1.00 [0.48–2.13]

0.819

 ALT, IU/L

19.5 [7–45]

41 [11–75]

0.004**

 GGTP, IU/L

59.5 [14–264]

92 [11–359]

0.262

 AVP, pg/mL

1.35 [0.8–5.1]

2.3 [1.2–6.3]

0.026*

 Aldosterone, pg/mL

113 [18–407]

316 [107–1200]

0.013*

 Serum osmolality, mOsm/kg. H2O

286 [250–290]

282 [273–295]

0.880

 Urine osmolality, mOsm/kg. H2O

448 [272–691]

452 [59–838]

0.350

Body Compositions; baseline

 BMI, kg/m2

23.1 [17.6–32.7]

23.7 [16.7–27.7]

0.574

 Skeletal muscle index, kg/m2

9.1 [7.4–16.0]

9.3 [7.1–11.5]

0.603

 TBWBIA-c a, L/m2

20.2 [18.0–22.5]

20.8 [17.9–24.0]

0.575

 ECWBIA-c a, L/m2

8.3 [7.2–9.2]

8.3 [6.7–10.1]

0.755

 ICWBIA-c a, L/m2

12.0 [10.5–13.7]

12.4 [9.6–14.0]

0.418

 ECWBIA/TBWBIA

0.40 [0.38–0.43]

0.40 [0.37–0.46]

0.418

  1. Data are shown as median with the range within brackets, or numbers
  2. Abbreviations: M Male, F Female, HCV Hepatitis virus C, MELD Model for end-stage liver disease, MAP Mean arterial pressure, PT-INR Prothrombin time- international ratio, BUN Blood urea nitrogen, ALT Alanine transaminase, GGTP γ- glutamyl transpeptidase, AVP Arginine vasopressin, BMI Body mass index, TBW Total body water, BIA Bioimpedance analysis, ECW Extracellular water, ICW Intracellular water
  3. *, P < 0.05; **, P < 0.01; ***, P < 0.0001
  4. aTBWBIA-c, ECWBIA-c, ICWBIA-c were normalized by body surface area (m2)